[go: up one dir, main page]

WO2022086127A1 - Composition destinée à prévenir ou traiter une affection abdominale inflammatoire comprenant un extrait de plantes médicinal complexe - Google Patents

Composition destinée à prévenir ou traiter une affection abdominale inflammatoire comprenant un extrait de plantes médicinal complexe Download PDF

Info

Publication number
WO2022086127A1
WO2022086127A1 PCT/KR2021/014596 KR2021014596W WO2022086127A1 WO 2022086127 A1 WO2022086127 A1 WO 2022086127A1 KR 2021014596 W KR2021014596 W KR 2021014596W WO 2022086127 A1 WO2022086127 A1 WO 2022086127A1
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory bowel
bowel disease
baekduong
herbal extract
hwangryeon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2021/014596
Other languages
English (en)
Korean (ko)
Inventor
이두석
이원우
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helixmith Co Ltd
Original Assignee
Helixmith Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helixmith Co Ltd filed Critical Helixmith Co Ltd
Publication of WO2022086127A1 publication Critical patent/WO2022086127A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention is hwangryeon (Coptis Rhizome); Hyeonggae ( Schizonepeta tenuifolia Briquet); And it relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising a complex herbal extract of Ecliptae Herba or Pulsatillae Radix as an active ingredient.
  • the present invention relates to a food composition or feed composition for preventing or improving inflammatory bowel disease comprising the complex herbal extract as an active ingredient.
  • Inflammatory bowel disease is a chronic intractable disease in which chronic inflammation or ulceration occurs in the mucous membranes of the large intestine and small intestine, causing diarrhea and bloody stools, and the symptoms temporarily improve and then recur.
  • inflammatory bowel disease is clinically similar, it is classified into two diseases, ulcerative colitis and Crohn's disease, which are different from each other in histological, endoscopic and immunological aspects.
  • Ulcerative colitis is a disease in which erosions or ulcers are continuously formed on the mucous membrane of the large intestine.
  • systemic symptoms such as Crohn's disease is a disease in which lesions such as ulcers occur discontinuously in any part of the digestive tract from the mouth to the anus. appears.
  • sulfasalazine an aminosalicylic acid product
  • side effects such as nausea, vomiting, anorexia, rash, headache, liver damage, leukopenia, abnormal red blood cells, proteinuria, and diarrhea.
  • strong side effects such as necrosis of the femoral head.
  • Infliximab a TNF- ⁇ monoclonal antibody, was used to treat Crohn's disease patients after it was approved by the US FDA as a treatment for Crohn's disease in 1998. is appearing Therefore, there is an urgent need to develop a new therapeutic agent for inflammatory bowel disease that is safe and has fewer side effects than the currently used inflammatory bowel disease treatment.
  • Coptis Rhizome is a herbaceous perennial plant of the Ranunculaceae family. ) ( Coptis chinensis Franchet), ) ( Coptis deltoidea CY Cheng et Hsiao) or Unryeon ( Coptis teeta Wallich), with the root removed. Yellow lily is detoxifying by detoxifying heat and heat, releasing heat and heat, and detoxification of fire. It belongs to ⁇ , and it is the removal of the fire and heat of the heart or stomach (four heart) and the removal of burnt things ( ⁇ ) at the same time. It is effective in regulating ( ⁇ ). Also, whole reading ( ), is known to be used for pathologies such as Changyang fever poison ( ⁇ ), and is known to have pharmacological effects such as antimicrobial action, blood pressure lowering action, and anti-inflammatory action.
  • Hyeonggae ( Schizonepeta tenuifolia Briquet) is an annual plant belonging to the Lamiaceae ( Labiatae ), and its above-ground part, Hyeonggae (Schizonepetae Herba) or the ear of flower (Schizonepetae Spica), is used medicinally.
  • Hyeonggae (Schizonepetae Herba) or the ear of flower (Schizonepetae Spica)
  • Chinese medicine it is used for symptoms of chills, fever, headache and sweating due to external sensitivities. It is used when there is fever and inflammation is spreading in the early stage of Changyang, and when it is roasted black, it has a hemostatic effect on hematemesis, discoloration, nosebleeds, urine bleeding, and uterine bleeding.
  • Herba is an annual herb of the Compositae family, and is an outpost of Eclipta prostrata Linne. It is also called Aejangcho, Mokhanryun, Mukducho, and Haryuncho. Hanryeoncho is known to have the effects of hemostasis, boeum, bosin, etc., and to strengthen muscles and bones.
  • Paekduong Pulsatillae Radix
  • Nogocho a dried root of a common root plant such as Pulsatilla koreana Nakai or Pulsatilla chinensis Regel, which is a perennial plant belonging to Ranunculaceae .
  • the inventors of the present invention showed that when using the complex herbal extracts of H.
  • the present invention was completed by finding an excellent therapeutic effect, particularly at a specific mixing ratio.
  • an object of the present invention is hwangryeon; brother-in-law; And to provide a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease comprising a herbal extract of orchid or baekduong as an active ingredient.
  • Another object of the present invention is hwangryeon; brother-in-law; And to provide a food composition or feed composition for the prevention or improvement of inflammatory bowel disease comprising a herbal extract of orchid or baekduong as an active ingredient.
  • Another object of the present invention is hwangryeon; brother-in-law; And to provide a method for preventing, improving or treating inflammatory bowel disease, comprising administering to a subject a pharmaceutical composition or a food composition comprising a herbal extract of orchid or baekduong as an active ingredient.
  • Another object of the present invention is hwangryeon; brother-in-law; And it is to provide a use for preventing, improving or treating inflammatory bowel disease of the herbal extract of orchid or baekduong.
  • the inventors of the present invention showed that when using the complex herbal extracts of H. It is effective, and especially in a specific mixing ratio, an excellent therapeutic effect was found.
  • the present invention is hwangryeon; brother-in-law; And it provides a pharmaceutical composition, food composition or feed composition for the prevention, improvement or treatment of inflammatory bowel disease comprising a herbal extract of orchid or baekduong as an active ingredient, and a method for preventing, improving or treating inflammatory bowel disease using the same.
  • the present invention is hwangryeon; brother-in-law; And it provides a pharmaceutical composition for preventing or treating inflammatory bowel disease comprising a herbal extract of orchid or baekduong as an active ingredient.
  • the herbal extract is Hwangryeon; brother-in-law; And Hanryeoncho or Baekduong 1.5-15: 1: It may be a mixture in a weight ratio of 0.1-15.
  • the term "crude herbal extract” or “composite herbal extract” refers to an active ingredient of the pharmaceutical composition of the present invention, which includes extracts of Hwangryeon lily, Hyeonggae, Orchidaceae or Baekduong, or extracts extracted from each herbal mixture. it means.
  • “Coptis Rhizome” of the present invention refers to herbal medicines, which are perennial herbaceous plants of the Ranunculaceae , and Coptis japonica Makino, Chinese rhizome ( ) ( Coptis chinensis Franchet), ) ( Coptis deltoidea CY Cheng et Hsiao) or Unryeon ( Coptis teeta Wallich) refers to a rhizome from which the root has been removed.
  • Hyeonggae ( Schizonepeta tenuifolia Briquet) of the present invention means an annual plant belonging to the Lamiaceae ( Labiatae ), and its above-ground part, Hyeonggae (Schizonepetae Herba) or ear (flower stalk), Hyeonggae (Schizonepetae Spica) include
  • Ecliptae Herba of the present invention refers to an annual grass of the Compositae family, and is an outpost of Eclipta prostrata Linne, which is also referred to as Aejangcho, Moxa chrysanthemum, Mukducho, Haryeoncho, etc. .
  • “Baekduong (Pulsatillae Radix)” of the present invention is called Nogocho, and refers to the dried root of a coexisting plant such as Pulsatilla koreana Nakai or Pulsatilla chinensis Regel, which is a perennial plant belonging to Ranunculaceae . .
  • the extracts of Hwangryeon, Hyeonggae, Orchidaceae, and Baekduong extracts contained in the composition of the present invention are natural plant materials and have been used as food and folk medicine for a long time, the extract of the present invention extracted therefrom is also expected to have no problems such as toxicity and side effects. can do. Therefore, the extracts of Hwangryeon, Hyeonggae, Hanryeoncho, and Baekduong extract can be used in medicines, foods, feeds, and the like.
  • inflammatory bowel disease refers to a disease in which inflammation occurs in the intestines, that is, the small intestine and large intestine, and includes diseases in which abnormal chronic inflammation in the intestinal tract repeats improvement and recurrence. It also includes specific enteritis with known etiology, nonspecific enteritis of unknown cause, and enteritis resulting from other diseases, such as entero-Behcet's disease, and the like.
  • treatment refers to any action in which symptoms of inflammatory bowel disease are improved or cured by administration of the composition according to the present invention.
  • prevention refers to any action that suppresses or delays symptoms of inflammatory bowel disease by administration of the composition according to the present invention.
  • the term "comprising as an active ingredient” means including an amount sufficient to achieve the efficacy or activity of the extract of the present invention.
  • the pharmaceutical composition of the present invention may further include extracts of other herbal medicines known in the art to have the same or similar effects as those exhibited by the composition of the present invention.
  • the pharmaceutical composition of the present invention may further include an active ingredient known to have an inflammatory bowel disease treatment effect in the art. More specifically, the pharmaceutical composition is a glucocorticosteroid, such as steroids, sulfasalazine, mesalazine, such as 5-aminosalicylic acid (5-aminosalicylic acid, 5-ASA) drug, TNF It may further include one or more active ingredients selected from the group consisting of - ⁇ monoclonal antibodies.
  • the pharmaceutical composition of the present invention may further include an active ingredient that has an effect on diseases other than inflammatory bowel disease.
  • the herbal extract of the present invention When used together with an additional active ingredient, the herbal extract and the additional active ingredient may be administered simultaneously as one formulation, or may be administered simultaneously or sequentially as separate formulations.
  • the pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, hormone therapy, drug therapy, or a biological response modifier to treat inflammatory bowel disease.
  • the herbal extract used in the present invention can be obtained using a conventional extraction solvent known in the art.
  • a polar solvent or a non-polar solvent may be used.
  • the polar solvent includes water, a C 1 to C 6 alcohol (eg, methanol, ethanol, propanol, butanol, n-propanol, iso-propanol and n-butanol, etc.), acetic acid, or a mixture of the above polar solvents.
  • Non-polar solvents include acetone, acetonitrile, ethyl acetate, methyl acetate, butyl acetate, fluoroalkane, hexane, ether, chloroform, dichloromethane or mixtures of the above non-polar solvents.
  • the herbal extract is extracted with a solvent selected from the group consisting of water, C 1 to C 6 alcohol, acetic acid, and a mixed solvent thereof.
  • the herbal extract is extracted with 0.01 to 90% ethanol. More specifically, the herbal extract is 0.01 to 90%, 1 to 90%, 10 to 90%, 20 to 90%, 30 to 90%, 40 to 90%, 50 to 90%, 60 to 90%, 0.01 to Extracted with 80%, 1-80%, 10-80%, 20-80%, 30-80%, 40-80%, 50-80% ethanol. Most specifically, the herbal extract is extracted with 60 to 80% ethanol.
  • the herbal extract is extracted through hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction, or a conventional extraction method known in the art.
  • extract has a meaning commonly used in the art as a crude extract, but broadly includes a fraction obtained by additionally fractionating the extract. That is, the herbal extract includes not only those obtained using the above-described solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatographs (those prepared for separation according to size, charge, hydrophobicity or affinity), etc. The fraction obtained through the purification method is also included in the herbal extract of the present invention.
  • the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carriers are those commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
  • a lubricant e.g., a talc, a kaolin, a kaolin, a kaolin, a kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, a talct, a talct, a talct, a stevia, glycerin, glycerin, glycerin,
  • the pharmaceutical composition is a powder, granule, tablet, coated tablet, pill, dragee, capsule, liquid, suspension, gel, syrup, slurry, suppository, enema, emulsion, It may be formulated as pastes, ointments, creams, lotions, powders, sprays or suspensions.
  • the pharmaceutical composition is formulated as a solid preparation such as tablets, pills, powders, granules or capsules for oral administration or liquid preparations such as suspensions, internal solutions, emulsions or syrups.
  • the pharmaceutical composition may be formulated as a sterile aqueous solution, non-aqueous solution, suspension, emulsion, freeze-drying agent or suppository for parenteral administration.
  • the pharmaceutical composition may further include an appropriate carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition.
  • an appropriate carrier for example, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, mannitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil.
  • a suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and response sensitivity of the patient, An ordinarily skilled physician can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis.
  • the daily dose of the pharmaceutical composition of the present invention is 1-100 mg/kg.
  • the inflammatory bowel disease is Crohn's disease, ulcerative colitis, enteric Behcet's disease, intestinal tuberculosis, hemorrhagic rectal ulcer, indeterminate colitis, bacterial enteritis, viral enteritis, amoebic enteritis and ischemic enteritis It may be a disease selected from the group consisting of colitis, but is not limited thereto.
  • the herbal extract is hwangryeon; brother-in-law; And Hanryeoncho is mixed in a weight ratio of 1.5-15: 1: 0.1-15. More specifically, the herbal extract is Hwangryeon; brother-in-law; and chrysanthemum 1.5-10: 1: 0.1-15, 1.5-7.5: 1: 0.1-15, 1.5-15: 1: 0.1-10, 1.5-10: 1: 0.1-10, 1.5-7.5: 1: 0.1 -10, 1.5-7 : 1 : 0.1-10, 1.5-5 : 1 : 0.1-10, 1.5-4 : 1 : 0.1-10, 1.5-3.5 : 1 : 0.1-10, 1.5-3 : 1 : 0.1 -10, 2-7 : 1 : 0.1-10, 2-5 : 1 : 0.1-10, 2-4 : 1 : 0.1-10, 2-3.5 : 1 : 0.1-10, 2-3 : 1 : 0.1 -10, 1.5-7.5 : 1 : 0.1-8, 1.5-7.5 : 1 :
  • the herbal extract is Hwangryeon; brother-in-law; And Hanryeonchoga 2-3: 1: weight ratio of 0.2-0.4, more specifically, the herbal extract is Hwangryeon; brother-in-law; And Hanryeoncho, when mixed in a weight ratio of 2.5: 1: 0.3 (15: 6: 2) shows the most excellent effect.
  • the herbal extract is hwangryeon; brother-in-law; And Baekduong 1.5-15: 1: It is mixed in a weight ratio of 0.1-15. More specifically, the herbal extract is Hwangryeon; brother-in-law; and Whitehead 1.5-15: 1: 0.1-10, 1.5-15: 1: 0.1-5, 1.5-15: 1: 0.1-2, 1.5-10: 1: 0.1-2, 1.5-9: 1: 0.1 -2, 1.5-7 : 1 :0.1-2, 1.5-5 : 1 : 0.1-2, 1.5-3 : 1 : 0.1-2, 2-10 : 1 : 0.1-2, 2-9 : 1 : 0.1 -2, 2-7: 1: 0.1-2, 2-5: 1: 0.1-2, 2-3: 1: 0.1-2, 1.5-15: 1: 0.1-1.5, 1.5-15: 1: 0.1 -1, 1.5-15: 1: 0.1-0.9, 1.5-15: 1: 0.1-0.7, 1.5-15: 1: 0.1-0.5, 1.5-15: 1: 0.1-0.3, 1.5-10: 1: 1:
  • the herbal extract is Hwangryeon; brother-in-law; And Baekduonggi 2-3: 1: 0.1-0.3 weight ratio, more specifically, the herbal extract is Hwangryeon; brother-in-law; And when Baekduong is mixed in a weight ratio of 2.5: 1: 0.2, the best effect is exhibited.
  • the present invention is hwangryeon; brother-in-law; And it provides a food composition for preventing or improving inflammatory bowel disease comprising a herbal extract of orchid or baekduong as an active ingredient.
  • the herbal extract is Hwangryeon; brother-in-law; And Hanryeoncho or Baekduong 1.5-15: 1: It may be a mixture in a weight ratio of 0.1-15.
  • the term “improvement” refers to any action of reducing a parameter related to a condition to be treated by administration of a composition comprising the extract of the present invention, for example, the severity of symptoms.
  • the food composition of the present invention may be prepared in the form of powder, granules, tablets, capsules or beverages.
  • various foods such as candy, drinks, gum, tea, vitamin complexes, or health supplements.
  • the food composition of the present invention includes health functional food and health food.
  • the food composition of the present invention can be taken for a long time.
  • the food composition of the present invention may include components commonly added during food production, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents.
  • examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose, oligosaccharides and the like; and polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • flavoring agents natural flavoring agents [taumatine, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
  • citric acid, high fructose, sugar, glucose, acetic acid, malic acid, fruit juice, licorice root extract, jujube extract, licorice extract, etc. may include
  • the present invention is hwangryeon; brother-in-law; And it provides a feed composition for preventing or improving inflammatory bowel disease comprising a herbal extract of orchid or baekduong as an active ingredient.
  • the herbal extract is Hwangryeon; brother-in-law; And Hanryeoncho or Baekduong 1.5-15: 1: It may be a mixture in a weight ratio of 0.1-15.
  • the pharmaceutical composition comprising the mixed herbal extract of the present invention as an active ingredient exhibits excellent therapeutic effects in inflammatory bowel disease, particularly Crohn's disease or ulcerative colitis, and can be used as a novel therapeutic agent.
  • the pharmaceutical composition of the present invention can be used as a safe therapeutic agent by reducing the side effects of existing therapeutic agents by including a natural product as an active ingredient.
  • % used to indicate the concentration of a specific substance is (weight/weight) % for solid/solid, (weight/volume) % for solid/liquid, and Liquid/liquid is (volume/volume) %.
  • the efficacy of the mixed herbal extract on inflammatory bowel disease, in particular, ulcerative colitis was confirmed.
  • the DSS-induced inflammatory bowel disease model is known to exhibit morphological changes and symptoms similar to those of human ulcerative colitis. Accordingly, after 8-week-old male mice (C57BL/6) were acclimatized for more than a week, Dextran Sulfate Sodium (DSS; 36,000-50,000 MW, MP Biomedicals, USA) was administered to induce ulcerative colitis.
  • DSS Dextran Sulfate Sodium
  • control group group administered with DSS and distilled water
  • Bowel disease is usually evaluated through clinical symptoms such as weight loss, diarrhea, and bloody stools.
  • the disease activity index is a method of analyzing the degree of intestinal disease by measuring weight loss rate, stool condition, and bleeding and assigning a score to each.
  • the normal group, the control group, and the experimental group were compared by analyzing the DAI by measuring the weight loss rate, stool status, and bleeding.
  • the DSS feeding method of the control group and the experimental group was prepared by diluting DSS in negative water to 2.5%, then feeding 100 mL of the DSS to the mice and replacing them every 2 days, DSS was fed for a total of 5 days.
  • mice in each group was measured and calculated as the weight loss rate, and the condition of stool and the presence or absence of bloody stool were checked.
  • scores were calculated according to the criteria in Table 2 below.
  • the normal group was orally administered 0.4 mL of distilled water once/day for 10 days from the start of the experiment.
  • the experimental group was administered 50 mg/kg of the single and mixed herbal extracts prepared in Preparation Example, and was orally administered once/day for 10 days from the start date of the experiment.
  • DAI Disease Activity Index
  • the normal group was orally administered 0.4 mL of distilled water once/day for 10 days from the start of the experiment.
  • the experimental group was administered 50 mg/kg of the single and mixed herbal extracts prepared in Preparation Example, and was orally administered once/day for 10 days from the start date of the experiment.
  • DAI Disease Activity Index
  • the mixed herbal extract group of Hwangryeon, Hyeonggae and Baekduong of the present invention has a lower DAI value and less weight change compared to the (negative) control group and the single herbal extract group (Comparative Examples 1, 2 and 4). was shown.
  • RAW264.7 cells were cultured in RPMI medium (Corning, USA) containing fetal bovine serum (Fetal Bovine Serum, FBS, Gibco TM , USA) and antibiotics (1% Penicillin, Streptomycin [P/S] Gibco-BRL, USA). cultured under Specifically, the incubator was maintained at a temperature of 37° C., and a gas mixed with 95% air and 5% CO 2 was continuously supplied so that appropriate conditions for cell culture were prepared. Cells were cultured 24 hours before the experiment so as to become 5x10 4 cells/well in a 24-well plate.
  • the (negative) control group and the LPS-treated group were pretreated with the cell culture solution for one hour after removing the supernatant of the prepared 24-well plate.
  • the experimental group was pre-treated with the single and complex herbal extracts prepared in Preparation Example for one hour.
  • each of the extracts was pretreated at a concentration of 10 ⁇ g/ml
  • each of the extracts was pretreated at a concentration of 20 ⁇ g/ml.
  • the (negative) control group was treated with the cell culture solution, and the LPS-treated group and the experimental group were treated with LPS at a concentration of 100 ng/ml for 24 hours. Thereafter, the supernatant was taken and the change in the nitric oxide content was evaluated by measuring the absorbance at 520 and 550 nm wavelength values through the Griess assay kit (G2930, Promega, USA). It was measured twice in the same way, and the results are shown in Table 5.
  • the mixed herbal extract group of Hwangryeon, Hyeonggae, and Orchid liana of the present invention exhibited lower NO-producing ability compared to the LPS-treated group and the single herbal extract group (Comparative Examples 1 to 3).
  • the (negative) control group and the LPS-treated group were pretreated with the cell culture solution for one hour after removing the supernatant of the prepared 24-well plate.
  • the experimental group was pre-treated with the single and complex herbal extracts prepared in Preparation Example for one hour.
  • the extracts were pretreated at a concentration of 10 ⁇ g/ml, respectively, and in the third (3 rd ) experiment, the extracts were pretreated at a concentration of 20 ⁇ g/ml, respectively.
  • the (negative) control group was treated with the cell culture solution, and the LPS-treated group and the experimental group were treated with LPS at a concentration of 100 ng/ml for 24 hours. Thereafter, the supernatant was taken and the change in the nitric oxide content was evaluated by measuring the absorbance at 520 and 550 nm wavelength values through the Griess assay kit (G2930, Promega, USA). It was measured three times in the same way, and the results are shown in Table 6.
  • the above ingredients are mixed and filled in an airtight bag to prepare a powder.
  • tablets are prepared by tableting according to a conventional tablet manufacturing method.
  • the above ingredients are mixed and filled in a gelatin capsule to prepare a capsule.
  • each component is added to purified water to dissolve it, an appropriate amount of lemon flavor is added, the above components are mixed, purified water is added, and purified water is added to the total amount to be adjusted to 100 ml, and then filled in a brown bottle. Sterilize to prepare a solution.
  • Vitamin B6 0.5 mg
  • composition ratio of the above vitamin and mineral mixture is a composition that is relatively suitable for health food in a preferred embodiment, but the mixing ratio may be arbitrarily modified. , to prepare granules, and can be used for preparing health food compositions according to a conventional method.
  • the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, then refrigerated. It is used to prepare the health drink composition of the invention.
  • composition ratio is prepared by mixing ingredients suitable for relatively favorite beverages in a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and national preferences such as demand class, demanding country, and use.
  • the present invention is hwangryeon (Coptis Rhizome); Hyeonggae ( Schizonepeta tenuifolia Briquet); And it relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising a complex herbal extract of Ecliptae Herba or Pulsatillae Radix as an active ingredient.
  • the present invention relates to a food composition or feed composition for preventing or improving inflammatory bowel disease comprising the complex herbal extract as an active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour prévenir ou traiter une affection abdominale inflammatoire, contenant, en tant que principes actifs, des extraits de plantes médicinaux de rhizome de Coptis, de Schizonepeta tenuifolia et d'herbe d'Ecliptae ou de racine de Pulsatillae. De plus, la présente invention concerne une composition d'aliment pour l'homme ou une composition d'aliment pour animaux pour la prévention ou l'atténuation d'une affection abdominale inflammatoire, comprenant l'extrait de plante médicinal en tant que principe actif.
PCT/KR2021/014596 2020-10-21 2021-10-19 Composition destinée à prévenir ou traiter une affection abdominale inflammatoire comprenant un extrait de plantes médicinal complexe Ceased WO2022086127A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200137043 2020-10-21
KR10-2020-0137043 2020-10-21

Publications (1)

Publication Number Publication Date
WO2022086127A1 true WO2022086127A1 (fr) 2022-04-28

Family

ID=81289989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/014596 Ceased WO2022086127A1 (fr) 2020-10-21 2021-10-19 Composition destinée à prévenir ou traiter une affection abdominale inflammatoire comprenant un extrait de plantes médicinal complexe

Country Status (2)

Country Link
KR (1) KR20220053486A (fr)
WO (1) WO2022086127A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102760746B1 (ko) * 2022-06-16 2025-02-04 강원대학교 산학협력단 땃두릅나무 및 한련초의 복합추출물을 유효성분으로 포함하는 항염증 및 항알레르기용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140126661A (ko) * 2013-04-23 2014-10-31 경희대학교 산학협력단 복합 추출물을 포함하는 대장염 예방, 개선 또는 치료용 조성물
KR20150040068A (ko) * 2013-10-04 2015-04-14 원광대학교산학협력단 한련초 추출물을 유효성분으로 함유하는 대장염의 예방, 개선 또는 치료를 위한 조성물
KR20170014758A (ko) * 2015-07-31 2017-02-08 일동제약(주) 혼합 생약 추출물을 포함하는 만성 염증성 질환의 예방, 치료 또는 개선용 조성물
WO2021071269A1 (fr) * 2019-10-10 2021-04-15 주식회사 헬릭스미스 Composition pour la prévention ou le traitement d'une maladie intestinale inflammatoire comprenant des extraits de plantes médicinales complexes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200009210A1 (en) 2016-12-20 2020-01-09 Seoul National University Hospital Pharmaceutical Composition Comprising Indigo Pulverata Levis Extract or Fraction Thereof as Effective Ingredient for Preventing or Treating Inflammatory Bowel Disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140126661A (ko) * 2013-04-23 2014-10-31 경희대학교 산학협력단 복합 추출물을 포함하는 대장염 예방, 개선 또는 치료용 조성물
KR20150040068A (ko) * 2013-10-04 2015-04-14 원광대학교산학협력단 한련초 추출물을 유효성분으로 함유하는 대장염의 예방, 개선 또는 치료를 위한 조성물
KR20170014758A (ko) * 2015-07-31 2017-02-08 일동제약(주) 혼합 생약 추출물을 포함하는 만성 염증성 질환의 예방, 치료 또는 개선용 조성물
WO2021071269A1 (fr) * 2019-10-10 2021-04-15 주식회사 헬릭스미스 Composition pour la prévention ou le traitement d'une maladie intestinale inflammatoire comprenant des extraits de plantes médicinales complexes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUH, S. Y. ET AL.: "Systems pharmacological approach of Pulsatillae radix on treating crohn's disease", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2017, no. 4198035, 2017, pages 1 - 21, XP055800455, DOI: 10.1155/2017/4198035 *
ZHOU, H. ET AL.: "The effect of berberine chloride on experimental colitis in rats in vivo and in vitro", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 294, no. 3, 2000, pages 822 - 829, XP009527312 *

Also Published As

Publication number Publication date
KR20220053486A (ko) 2022-04-29

Similar Documents

Publication Publication Date Title
WO2010104309A9 (fr) Compositions pour prévenir ou améliorer des maladies gastro-intestinales
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2016032249A1 (fr) Composition pharmaceutique contenant un extrait de vaccinium bracteatum thunb. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2021071269A1 (fr) Composition pour la prévention ou le traitement d'une maladie intestinale inflammatoire comprenant des extraits de plantes médicinales complexes
WO2019177428A1 (fr) Composition de matière première de médicament pour prévenir ou traiter des maladies respiratoires
WO2022086127A1 (fr) Composition destinée à prévenir ou traiter une affection abdominale inflammatoire comprenant un extrait de plantes médicinal complexe
WO2013141581A1 (fr) Composition pharmaceutique ou aliment naturel comprenant des extraits de fruit de lonicera coerulea var. edulis en tant que principes actifs dans la prévention ou l'amélioration de maladies vasculaires cérébrales ischémiques
WO2014027832A1 (fr) Composition pour la prévention ou le traitement d'une colite
WO2011099812A2 (fr) Composition de prévention ou de traitement de l'infection à rotavirus, contenant un extrait de réglisse
WO2020242113A1 (fr) Composition pour la prévention, le soulagement ou le traitement du syndrome métabolique accompagné de l'obésité et/ou du diabète, contenant, en tant que principe actif, un complexe (complexe ib) d'extrait de groseille indienne et d'extrait d'orge jeune
WO2016010340A1 (fr) Composition pour prévenir et traiter l'inflammation ou les maladies allergiques contenant un extrait de gynura procumbens en tant que principe actif, et son utilisation
WO2011139118A2 (fr) Composition pharmaceutique et composition d'aliment naturel fonctionnel pour la prévention, le traitement ou l'amélioration de maladies de type dyskinésie gastro-intestinale
WO2023003193A1 (fr) Composition comprenant de la paeoniflorine pour la prévention ou le traitement de la cachexie et de la perte musculaire
WO2018221922A1 (fr) Composition pour la prévention et le traitement de maladies musculaires, contenant un extrait de coptidis rhizoma, et son utilisation
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2020256464A1 (fr) Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production
WO2012108634A2 (fr) Composition permettant de prévenir ou de traiter une maladie respiratoire contenant un mélange d'extraits d'herbes constitué de racine de cnidium officinale et de corydale à tubercule
WO2009151236A2 (fr) Composition comprenant des extraits ou fractions de magnolia obovata thunb. utilisable pour le traitement et la prévention des affections inflammatoires
WO2023017958A1 (fr) Composition pour la prévention, le traitement ou le soulagement de l'arthrite, comprenant un extrait d'elaeocarpus sylvestris ou un mélange d'extrait d'elaeocarpus sylvestris et de sulfasalazine en tant que principe actif
WO2022182199A1 (fr) Composition contenant un extrait à l'eau chaude de cassis pour prévenir, soulager ou traiter les maladies du foie gras non alcooliques
WO2023055079A1 (fr) Composition pour prévenir, atténuer ou traiter un syndrome métabolique, comprenant un extrait de caroube
WO2015105373A1 (fr) Composition pour la prévention ou le traitement de l'asthme, comprenant un extrait de l'e uonymus alatus ou une fraction de ce dernier
WO2015002430A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'asthme comprenant un extrait de pistacia weinmannifolia j. poiss. ex franch ou une fraction de celui-ci
WO2016204493A1 (fr) Nouveau composé (ks 513) isolé de pseudolysimachion rotundum var. subintegrum, la composition le comprenant comme ingrédient actif pour la prévention ou le traitement de l'allergie, d'une maladie inflammatoire, de l'asthme ou d'une maladie pulmonaire obstructive chronique et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21883196

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21883196

Country of ref document: EP

Kind code of ref document: A1